| Autor: |
Mehmet Ali Eryilmaz, Cigdem Damla Cetinkaya, İbrahim Solak, Ayse Boyaci, Mustafa Solak, Duygu İlke Yildirim |
| Jazyk: |
English<br />Turkish |
| Rok vydání: |
2018 |
| Předmět: |
|
| Zdroj: |
Family Practice and Palliative Care, Vol 3, Iss 3, Pp 123-126 (2018) |
| Druh dokumentu: |
article |
| ISSN: |
2459-1505 |
| DOI: |
10.22391/fppc.467700 |
| Popis: |
Introduction: Netrin-1has been shown to induce angiogenesis and is considered to function as aproto-oncogene. We aimed to evaluate the relationship of serum netrin-1 levelwith the presence of breast mass and the nature of mass.Methods: A total of84 patients, including 27 patients with benign mass, 31 patients with malignantmass and 26 healthy controls, were enrolled in the study. Results: In ourstudy, the mean serum netrin-1 level was 479±325 pg/ml in the patients withmalignant mass, 336.9±178.2 pg/ml in the patients with benign mass and264.7±112.4 pg/ml in the healthy controls, respectively. There was astatistically significant difference in mean serum netrin-1 level between thesethree groups (p=0.007). When the patients participating in the study weredivided in to two groups as those with (the benign and malign groups) andwithout (the control group) mass, the mean serum netrin-1 level was 264.7±112.4pg/ml in those without mass and 412.8±274.2 pg/ml in those with mass,respectively. It was seen that the mean serum netrin-1 level of those with masswas statistically significantly higher than that of those without mass(p=0.016).Conclusion: The meanserum netrin-1 level was found to be significantly higher in the patients withbreast mass, especially those with malignant mass. |
| Databáze: |
Directory of Open Access Journals |
| Externí odkaz: |
|
